Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest from Joseph Haas
CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.
On a quarterly earnings call that touched on Trump administration policy impacts, Merck said it is well positioned for changes coming from the new administration.
Deal snapshot: The Flagship portfolio firm will use its Decode platform to seek novel targets for an unspecified autoimmune disease, with Genentech holding license rights.
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.